Top Markets
Coin of the day
Sinphar Pharmaceutical Co. Ltd. Sinphar Pharmaceutical Co. Ltd.

Sinphar Pharmaceutical Co. Ltd.

1734
Rangering i aksjer #18495
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the... Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and other products; and healthy food under the Sinphar, DailyCare, Migus, YouBest, and SynCoreBio brands. It also provides moisturizer repair essence, anti aging cream, renewable oi, and UV defence cream under the DYNASKIN brand; serum, revitalizing cream, hygiene, sunblock, sunscreen, and lightening tables under the Yestuner brand; and shower gel and hair shampoo. In addition, the company is involved in the provision of testing and development, as well as product design and manufacturing services. The company was incorporated in 1977 and is based in Yilan City, Taiwan.
Aksjekurs
$0.97305026
Markedsverdi
$196.18M
Endring (1 dag)
-0.16%
Endring (1 år)
0.50%
Land
TW
Handel Sinphar Pharmaceutical Co. Ltd. (1734)

Kategori

Inntekter for Sinphar Pharmaceutical Co. Ltd. (1734)
Inntekter i 2026 TTM: 0
Ifølge Sinphar Pharmaceutical Co. Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Sinphar Pharmaceutical Co. Ltd. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter